Portugal-based Bial reported that pariceract (BIA 28-6156; formerly LTI-291, LTI-00291), its oral small-molecule allosteric activator of beta-glucocerebrosidase (GCase), failed to slow disease progression in patients with GBA1 gene-associated Parkinson's disease, ending development of what had been one of the few mechanism-specific candidates in this genetically defined population. The result closes a program that had enrolled 273 patients across 85 sites in Europe and North America, and deals a further setback to the GCase activation hypothesis in GBA-associated Parkinson's disease — a subtype affecting an estimated 5%-15% of all Parkinson's patients and typically characterized by faster motor progression and earlier cognitive decline than idiopathic disease.
The ACTIVATE trial was a Phase IIb, multicenter, randomized, double-blind, placebo-controlled study evaluating pariceract in genetically confirmed GBA-PD patients across two fixed oral doses (10 mg/day and 60 mg/day). Enrollment of 273 patients took approximately 18 months, with sites spanning 11 countries. The study assessed efficacy, safety, tolerability, pharmacodynamics, and pharmacokinetics. Bial announced the first patient to complete the full dose regimen in January 2025, with topline data expected mid-2026.
Neither the primary endpoint nor the key secondary efficacy endpoints were met. Bial did not disclose the specific primary endpoint measure or numerical efficacy data in the topline release, stating only that pariceract "failed to slow the progression of GBA-PD versus placebo". The drug was reported as generally well tolerated, with no unexpected safety concerns identified — a finding that does not rescue the program but may inform future mechanistic work in the field. Based on the absence of demonstrated efficacy, Bial has discontinued further development of pariceract for this indication.
Competitive context
The GCase activation space has now accumulated two high-profile clinical failures in rapid succession. In May 2026, Biogen (Nasdaq: BIIB) and Denali Therapeutics (Nasdaq: DNLI) reported that BIIB122 (DNL151), a small-molecule LRRK2 inhibitor, failed its Phase IIb LUMA study in early-stage idiopathic Parkinson's disease — a different target but another genetically informed disease-modification strategy that did not translate into clinical benefit. While the LUMA failure involved a distinct mechanism and broader patient population, it reinforces the difficulty of demonstrating disease modification in Parkinson's with current trial designs and endpoints.
Within the GCase space specifically, competitors remain active at earlier stages. Maryland-based Gain Therapeutics (Nasdaq: GANX) is advancing GT-02287, a GCase allosteric modulator, in a Phase Ib extension study in patients with Parkinson's disease with or without a GBA1 mutation. Interim data presented in May 2026 showed stable MDS-UPDRS scores over 150 days and a differential response pattern in patients with elevated baseline cerebrospinal fluid glucosylsphingosine, a GCase substrate biomarker — though the study was not designed to assess clinical efficacy. Chicago-based Vanqua Bio reported Phase Ib data in March 2026 showing that VQ-101, another oral GCase activator, achieved greater than 50% activation of lysosomal GCase in GBA-Parkinson's patients, meeting a pre-specified target engagement goal. Both programs remain substantially earlier in development than pariceract was at the time of its failure.